First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Subscribe To Our Newsletter & Stay Updated
